Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.

, , ,
doi.org/10.1093/eurheartj/sul064, hdl.handle.net/1765/68624
European Heart Journal Supplements
Department of Cardiology

Siminiak, T, Meliga, E, Jerzykowska, O, & Serruys, P.W.J.C. (2006). Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury. European Heart Journal Supplements (Vol. 8). doi:10.1093/eurheartj/sul064